These outcomes, together with a former report demonstrating that a little-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like habits in mice,2 guidance the notion of focusing on ACKR3 as a unique way to modulate the opioid process, which could open new therapeutic avenues for opioid-associate